Dr. Reddy’s Q4FY26 profit after tax drops 86% YoY to ₹ 2,201 million

• Dr. Reddy’s Laboratories posted Q4FY26 revenue of ₹ 75,162 Mn, down 11.6% YoY and 13.9% QoQ; profit attributable to equity holders fell 86% YoY to ₹ 2,201 Mn.
• EBITDA dropped to ₹ 9,807 Mn, with margin narrowing to 13% from 29.1% a year earlier.
• North America revenue slid 51% YoY to ₹ 17,562 Mn, while Emerging Markets climbed 29% to ₹ 18,057 Mn and India rose 20% to ₹ 15,663 Mn.
• FY26 revenue increased 3.2% to ₹ 335,933 Mn, while profit attributable to equity holders declined 24% to ₹ 42,850 Mn.
• GV Prasad cited lower lenalidomide sales and one-offs; updates included Canada compliance for generic semaglutide injection, India launch of semaglutide injection under Obeda, and USFDA acceptance for review of the BLA for IV abatacept biosimilar.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.